Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin-EIR dose-ranging in moderate active Crohn's disease
2007-001014-17Phase 2Completed
- Sponsor
- Alfasigma
- Start
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rifaximin-EIR in Crohn's disease (4 arms), sponsored by Alfasigma. Primary endpoint: Clinical remission at week 12. Started Jun 2007; status: completed.
02
Drugs
rifaximin-EIR
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2007-001014-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001014-17.